Valerie Gouon-Evans, PharmD, PhD is Associate Professor of Medicine in the Section of Gastroenterology at the Chobanian and Avedisian School of Medicine, Director of the Program of Boston University Liver Biologists (BULB), and Associate Director of the Molecular & Translational Medicine (MTM) PhD Program of the Department of Medicine.
After completing her graduate studies in Paris, Dr. Gouon-Evans joined Dr. Pollard's Lab as a postdoctoral fellow where she studied mammary gland development and breast cancer. She then began her career as an Instructor of Gene and Cell Medicine at the Icahn School of Medicine at Mount Sinai School of Medicine in New York in the laboratory of Dr. Gordon Keller, where she pioneered protocols to efficiently generate hepatocyte-like cells from pluripotent stem cells. She quickly rose up the ranks and was promoted to Assistant Professor before arriving at Boston University. As a PharmD PhD lab leader for 16 years, Dr. Gouon-Evans has overseen the creation of a research program to advance understanding of liver development and establishing therapeutic strategies to alleviate liver disease using an induced pluripotent stem cell platform and mouse models. Recently, Dr. Gouon-Evans lab also pioneered an innovative technology to deliver regenerative factors to the liver to treat various liver diseases, by using mRNA complexed to lipid nanoparticles, which is a validated platform with the widely used mRNA-based COVID-19 vaccines.
Diversity, Equity, Inclusion and Accessibility
I am a strong believer in the power of diversity for advancing science. Developing daily awareness to equity, inclusion and belonging is critical to empower diversity, and is therefore a continuous societal endeavor I advocate and commit to in my lab, work environment and life in general. My willingness and dedication to increase this awareness and to implement actions toward diversity have been fed by two instrumental leadership training programs on the BU campus, the Woman Leadership program, and the Mid-career Faculty Leadership (MFL) program. Especially, the MFL program gave me the incredible opportunity to be part of a leader group who established a proposal for the program “Report. Respond. Restore” addressing interpersonal mistreatments at Boston University Chobanian and Avedisian School of Medicine, a program that if implemented would certainly help create a safer work environment where everybody can thrive.
Below are some specific examples of my Diversity, Equity, Inclusion, and Belonging activities. I mentor BU PREP students and train them for their coming PhD program applications through mock interviews. I mentor underrepresented undergraduate students and guide them in their future career path. As the co-director of the Molecular & Translational Medicine PhD program, I support recruitment of URG PhD students with financial compensation through the program. My lab has been an active participant in the anti-racism activities organized by the CReM and notably presented at the CReM anti-racism journal club series. As the first woman PI hired at the CReM, I take pride to continuously promote women in science especially women from diverse backgrounds from undergraduate to graduate levels. Overall, I believe that harnessing Diversity, Equity, Inclusion, and Belonging is a must for advancing science in a healthy environment where all thrive. Yet, I recognize that this is a societal work in progress, and I have the willpower and dedication to continue to implement my DEI effort in my daily life.
Member
Boston University
Center for Regenerative Medicine
Member
Boston University
Evans Center for Interdisciplinary Biomedical Research
Member
Boston University
Genome Science Institute
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Primary hepatocyte and engineered iPSC-derived hepatocyte-like cell transplantation to treat alpha-1 antitrypsin deficiencyassociated liver disease02/01/2023 - 05/31/2024 (Key Person / Mentor)
NIH/National Diabetes & Digestive & Kidney Diseases5F31DK135378-02
Sexual dimorphism of acetaminophen-induced liver injury and regeneration07/01/2021 - 10/31/2022 (Key Person / Mentor)
NIH/National Diabetes & Digestive & Kidney Diseases5F31DK127606-02
Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration07/01/2022 - 04/30/2027 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS5R01DK133404-02
Pre notification Promoting progenitor-driven liver regeneration as an AATD-associated liver disease therapy07/01/2024 - 06/30/2026 (PI)
Alpha-1 Foundation
A multi-modular approach for human pluripotent stem cell-based liver regeneration 09/15/2020 - 07/31/2025 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS1R01DK124361-01A1
Engineered and edited patient-derived iPSC for AATD-associated liver disease cell therapy07/01/2022 - 06/30/2025 (PI)
Alpha-1 Foundation
Edited stem cell-based therapy with transcript therapy for AATD-associated liver disease07/01/2019 - 06/30/2022 (PI)
Alpha-1 Foundation
Use of Human Pluripotent Stem Cell-derived Hepatic Cells in Pediatric Liver Transplantation07/01/2017 - 05/31/2018 (PI)
March of Dimes
Showing 10 of 17 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Smith AR, Rizvi F, Everton E, Adeagbo A, Wu S, Tam Y, Muramatsu H, Pardi N, Weissman D, Gouon-Evans V. Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice. Nat Commun. 2024 Jun 12; 15(1):5010.View Related Profiles. PMID: 38866762; PMCID: PMC11169405; DOI: 10.1038/s41467-024-49332-8;
-
Smith AR, Rizvi F, Everton E, Adeagbo A, Wu S, Tam Y, Muramatsu H, Pardi N, Weissman D, Gouon-Evans V. Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy to treat murine liver diseases. bioRxiv. 2024 Jan 11.View Related Profiles. PMID: 38260488; PMCID: PMC10802626; DOI: 10.1101/2024.01.11.575286;
-
Rizvi F, Lee YR, Diaz-Aragon R, Bawa PS, So J, Florentino RM, Wu S, Sarjoo A, Truong E, Smith AR, Wang F, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. Cell Stem Cell. 2023 Dec 07; 30(12):1640-1657.e8.View Related Profiles. PMID: 38029740; PMCID: PMC10843608; DOI: 10.1016/j.stem.2023.10.008;
-
Rizvi F, Lee YR, Diaz-Aragon R, So J, Florentino RM, Smith AR, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V. VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. bioRxiv. 2023 Apr 18. PMID: 37131823; PMCID: PMC10153196; DOI: 10.1101/2023.04.17.537186;
-
Everton E, Del Rio-Moreno M, Villacorta-Martin C, Singh Bawa P, Lindstrom-Vautrin J, Muramatsu H, Rizvi F, Smith AR, Tam Y, Pardi N, Kineman R, Waxman DJ, Gouon-Evans V. Growth Hormone Accelerates Recovery From Acetaminophen-Induced Murine Liver Injury. bioRxiv. 2023 Apr 18.View Related Profiles. PMID: 37131727; PMCID: PMC10153200; DOI: 10.1101/2023.04.17.537197;
-
Gouon-Evans V, Fiorotto R. Fibroblasts to hepatocytes: A nonstop flight into cell therapy for liver diseases? Hepatology. 2023 May 01; 77(5):1469-1471. PMID: 35957526
-
-
Smith AR, Gouon-Evans V. c-Maf: The magic wand that turns on LSEC fate. Cell Stem Cell. 2022 Apr 07; 29(4):491-493. PMID: 35395181
-
Everton E, Rizvi F, Smith AR, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA. Bio Protoc. 2021 Oct 05; 11(19):e4184.View Related Profiles. PMID: 34722830; PMCID: PMC8517647; DOI: 10.21769/BioProtoc.4184;
-
Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Author Correction: Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 May 10; 12(1):2825.View Related Profiles. PMID: 33972545; PMCID: PMC8110992; DOI: 10.1038/s41467-021-23322-6;
Showing 10 of 40 results.
Show More
-
Rizvi F, Everton E, Smith AR, Liu H, Osota E, Beattie M, Tam Y, Pardi N, Weissman D, Gouon-Evans V. Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA. Nat Commun. 2021 01 27; 12(1):613.View Related Profiles. PMID: 33504774; PMCID: PMC7840919; DOI: 10.1038/s41467-021-20903-3;
-
Han S, Tan C, Ding J, Wang J, Ma'ayan A, Gouon-Evans V. Endothelial cells instruct liver specification of embryonic stem cell-derived endoderm through endothelial VEGFR2 signaling and endoderm epigenetic modifications. Stem Cell Res. 2018 07; 30:163-170. PMID: 29936335; DOI: 10.1016/j.scr.2018.06.004;
-
Bardot E, Calderon D, Santoriello F, Han S, Cheung K, Jadhav B, Burtscher I, Artap S, Jain R, Epstein J, Lickert H, Gouon-Evans V, Sharp AJ, Dubois NC. Foxa2 identifies a cardiac progenitor population with ventricular differentiation potential. Nat Commun. 2017 02 14; 8:14428. PMID: 28195173; PMCID: PMC5316866; DOI: 10.1038/ncomms14428;
-
-
Goldman O, Gouon-Evans V. Human Pluripotent Stem Cells: Myths and Future Realities for Liver Cell Therapy. Cell Stem Cell. 2016 06 02; 18(6):703-6. PMID: 27257759; DOI: 10.1016/j.stem.2016.05.019;
-
Goldman O, Valdes VJ, Ezhkova E, Gouon-Evans V. The mesenchymal transcription factor SNAI-1 instructs human liver specification. Stem Cell Res. 2016 07; 17(1):62-8. PMID: 27240252; PMCID: PMC5012916; DOI: 10.1016/j.scr.2016.05.007;
-
-
Goldman O, Han S, Hamou W, Jodon de Villeroche V, Uzan G, Lickert H, Gouon-Evans V. Endoderm generates endothelial cells during liver development. Stem Cell Reports. 2014 Oct 14; 3(4):556-65. PMID: 25358784; PMCID: PMC4223703; DOI: 10.1016/j.stemcr.2014.08.009;
-
-
-
Sourisseau M, Goldman O, He W, Gori JL, Kiem HP, Gouon-Evans V, Evans MJ. Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection. Gastroenterology. 2013 Nov; 145(5):966-969.e7. PMID: 23891978; PMCID: PMC3805793; DOI: 10.1053/j.gastro.2013.07.026;
-
Goldman O, Han S, Sourisseau M, Sourrisseau M, Dziedzic N, Hamou W, Corneo B, D'Souza S, Sato T, Kotton DN, Bissig KD, Kalir T, Jacobs A, Evans T, Evans MJ, Gouon-Evans V. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell Stem Cell. 2013 Jun 6; 12(6):748-60.View Related Profiles. PMID: 23746980; PMCID: PMC3922205; DOI: 10.1016/j.stem.2013.04.026;
-
Cashman TJ, Gouon-Evans V, Costa KD. Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev. 2013 Jun; 9(3):254-65. PMID: 22577007; PMCID: PMC5868420; DOI: 10.1007/s12015-012-9375-6;
-
Han S, Bourdon A, Hamou W, Dziedzic N, Goldman O, Gouon-Evans V. Generation of functional hepatic cells from pluripotent stem cells. J Stem Cell Res Ther. 2012 Aug 15; Suppl 10(8):1-7. PMID: 25364624; PMCID: PMC4215546; DOI: 10.4172/2157-7633.S10-008;
-
Kubo A, Stull R, Takeuchi M, Bonham K, Gouon-Evans V, Sho M, Iwano M, Saito Y, Keller G, Snodgrass R. Pdx1 and Ngn3 overexpression enhances pancreatic differentiation of mouse ES cell-derived endoderm population. PLoS One. 2011; 6(9):e24058. PMID: 21931641; PMCID: PMC3172220; DOI: 10.1371/journal.pone.0024058;
-
Christodoulou C, Longmire TA, Shen SS, Bourdon A, Sommer CA, Gadue P, Spira A, Gouon-Evans V, Murphy GJ, Mostoslavsky G, Kotton DN. Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes. J Clin Invest. 2011 Jun; 121(6):2313-25.View Related Profiles. PMID: 21537085; PMCID: PMC3104741; DOI: 10.1172/JCI43853;
-
Green MD, Chen A, Nostro MC, d'Souza SL, Schaniel C, Lemischka IR, Gouon-Evans V, Keller G, Snoeck HW. Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells. Nat Biotechnol. 2011 Mar; 29(3):267-72. PMID: 21358635; PMCID: PMC4866999; DOI: 10.1038/nbt.1788;
-
Han S, Dziedzic N, Gadue P, Keller GM, Gouon-Evans V. An endothelial cell niche induces hepatic specification through dual repression of Wnt and Notch signaling. Stem Cells. 2011 Feb; 29(2):217-28. PMID: 21732480; PMCID: PMC3437666; DOI: 10.1002/stem.576;
-
-
Gadue P, Gouon-Evans V, Cheng X, Wandzioch E, Zaret KS, Grompe M, Streeter PR, Keller GM. Generation of monoclonal antibodies specific for cell surface molecules expressed on early mouse endoderm. Stem Cells. 2009 Sep; 27(9):2103-13. PMID: 19522011; PMCID: PMC2890285; DOI: 10.1002/stem.147;
-
Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn. 2006 Dec; 235(12):3222-9. PMID: 17029292; DOI: 10.1002/dvdy.20972;
-
Gouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler CI, Kubo A, Shafritz DA, Keller G. BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nat Biotechnol. 2006 Nov; 24(11):1402-11. PMID: 17086172; DOI: 10.1038/nbt1258;
-
Zhao X, Matsumoto N, Gouon-Evans V, Yea S, Loke JC, Keller G, Friedman SL. Hepatology. The role of kruppel-like factor 6 (KLF6) in differentiation of embryonic stem cells into hepatocytes. 2006.
-
Banaei-Bouchareb L, Gouon-Evans V, Samara-Boustani D, Castellotti MC, Czernichow P, Pollard JW, Polak M. Insulin cell mass is altered in Csf1op/Csf1op macrophage-deficient mice. J Leukoc Biol. 2004 Aug; 76(2):359-67. PMID: 15178709; DOI: 10.1189/jlb.1103591;
-
Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene. 2003 Sep 25; 22(41):6408-23. PMID: 14508521; DOI: 10.1038/sj.onc.1206737;
-
Gouon-Evans V, Pollard JW. Unexpected deposition of brown fat in mammary gland during postnatal development. Mol Endocrinol. 2002 Nov; 16(11):2618-27. PMID: 12403850; DOI: 10.1210/me.2001-0337;
-
Gouon-Evans V, Lin EY, Pollard JW. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res. 2002; 4(4):155-64. PMID: 12100741; PMCID: PMC138736
-
Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia. 2002 Apr; 7(2):147-62. PMID: 12465600
-
Gouon-Evans V, Pollard JW. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology. 2001 Oct; 142(10):4515-21. PMID: 11564717; DOI: 10.1210/endo.142.10.8459;
-
Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. Development. 2000 Jun; 127(11):2269-82. PMID: 10804170
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 5 |
| 2024 | 2 |
2010 Federation of American Societies for Experimental Biology (FASEB):
Travel Award
2008 Federation of American Societies for Experimental Biology (FASEB):
Travel Award
2007-2008 International Society for Stem Cell Research:
Travel Award